Clinical trial · Observational
CASE 1320: RAI Uptake and Serum Prolactin in Thyroid Cancer
Breast Uptake on Radioiodine Scan and Serum Prolactin in Thyroid Cancer Patients Prepared by Thyroid Hormone Withdrawal or Recombinant Human Thyrotropin: A Prospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Radioactive iodine (RAI) is a radioisotope used to ablate thyroid gland remnant after thyroidectomy in patients diagnosed with differentiated thyroid carcinoma (DTC). A whole body scan (WBS) is performed to not only evaluate for iodine uptake by the native thyroid tissue but also to observe for uptake in other areas of the body, which could be physiological or indicative of iodide-avid metastases. Research has shown a correlation between breast cancer and thyroid cancer. Patients with DTC have been found to have elevated levels of serum prolactin, which could lead to mammary gland dysfunction. In patients with DTC undergoing RAI scanning or therapy, it has been previously observed that patients prepared by thyroid hormone withdrawal have significantly higher breast uptake on whole body scan compared to those prepared by rh-TSH. Considering the impact of prolactin on breast tissue, this study aims to correlate these findings with the lab values and the method of preparation. Accordingly, the research question is as follows: does the method of WBS preparation impact prolactin levels and how does that correlate with breast uptake in patients with DTC undergoing RAI WBS?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Thyrogen (rh-TSH)
- description
- Group 1: Female patients prepared for radioactive iodine treatment by rh-TSH (Thyrogen)
- label
- Withdrawal from thyroid hormone
- description
- Group 2: Female patients prepared for radioactive iodine treatment by withdrawal from thyroid hormones
Primary outcomes (1)
- measure
- Breast uptake of I-131 on whole body radioactive iodine scan
- timeFrame
- 10 days after treatment
- description
- Breast uptake of I-131 on whole body radioactive iodine scan
Secondary outcomes (4)
- measure
- Change in serum prolactin concentration
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Female patients with diagnosis of differentiated thyroid carcinoma who have had thyroidectomy performed previously * Patients able to understand and sign informed consent for imaging * Patients already scheduled to undergo radioactive iodine whole body scanning (RAI WBS) Exclusion Criteria: * Males * Patients with a history of breast cancer * Patients with a known history of hyperprolactinemia * Patients receiving medications known to raise serum prolactin
References
Publications (0)
Data not yet available